Market Cap (In USD)
3.29 Billion
Revenue (In USD)
-
Net Income (In USD)
-36 Million
Avg. Volume
327.12 Thousand
- Currency
- USD
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 37.55-64.98
- PE
- -
- EPS
- -
- Beta Value
- 1.278
- ISIN
- KY61559X1045
- CUSIP
- 61559X104
- CIK
- 1821586
- Shares
- -
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Dr. Jorge Santos da Silva
- Employee Count
- -
- Website
- https://www.moonlaketx.com
- Ipo Date
- 2020-10-20
- Details
- MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or radiographic axial spondyloarthritis. MoonLake Immunotherapeutics was founded in 2021 and is headquartered in Zug, Switzerland.
More Stocks
-
7723
-
AMSWAAmerican Software, Inc.
AMSWA
-
GLITTEKGGlittek Granites Limited
GLITTEKG
-
IFCIIFCI Limited
IFCI
-
BCXBioceltix S.A.
BCX
-
NINTFNinety One Group
NINTF
-
SGR-UNSlate Grocery REIT
SGR-UN
-
CCOI